SLN

Rating neutralAI Memo

Silence Therapeutics

As of 2026-04-15/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

Second-quarter 2026 preclinical updates on SLN365 and SLN098 • 2026-06-30

Base target: $7 / p=45% prob

Biggest risk

The bear case is that SLN remains a narrow, single-major-readout story after collaboration revenue fell sharply in 2025 and the 10-K disclosed AstraZeneca will not pursue further SLN312 development beyond Phase 1, reducing partnership optionality [#PR-2026-03-05][#10-K-2026-03-05].

Invalidation

Break below $4 or thesis failure.

What would change my mind?

The bull case is that divesiran is the primary asset the market cares about and the company has already de-risked execution somewhat by finishing SANRECO enrollment ahead of schedule, with 3Q 2026 topline data now the key unlock [#PR-2025-10-23][#PR-2026-03-05].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-15

Base target

p=45%

Bull target

$11

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Strategic path for zerlasiran and balance-sheet endurance into 2028
The bull case is that divesiran is the primary asset the market cares about and the company has already de-risked execution somewhat by finishing SANRECO enrollment ahead of schedule, with 3Q 2026 topline data now the key unlock [#PR-2025-10-23][#PR-2026-03-05].
At roughly $280 million market cap against $85.1 million of year-end cash and investments, the stock looks inexpensive versus a successful Phase 2 outcome but not obviously cheap if SANRECO disappoints or slips, so valuation alone does not create a strong edge before data [#PR-2026-03-05][#10-K-2026-03-05].

BearKey bullets

AstraZeneca notified Silence on March 4, 2026 that it will not pursue further SLN312 development beyond Phase 1, reducing one external validation path.
Collaboration revenue dropped materially in 2025, increasing dependence on internal execution and future partnering.
Even with runway guided into 2028, prolonged delays or new trial costs could bring dilution risk back sooner than expected.

WatchKey bullets

Second-quarter 2026 preclinical updates on SLN365 and SLN098

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $7 (p=45%)

Target spread vs base: +69% / -46%

Scenario probabilities

Bull Target: $11 (p=25%)Base Target: $7 (p=45%)Bear Target: $4 (p=30%)

Commentary

Primary-source evidence supports a cautious monitoring stance rather than an outright bullish call. The company still has a credible lead catalyst in SANRECO Phase 2 topline data expected in 3Q 2026 and enough cash to reach that window, but the thesis is narrower than it looked previously because collaboration revenue stepped down and AstraZeneca will not advance SLN312 beyond Phase 1 [#PR-2026-03-05][#PR-2025-10-23][#10-K-2026-03-05].

As of 2026-04-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Strategic path for zerlasiran and balance-sheet endurance into 2028

Scenarios

Bull Target (Scenario probability)

$11 / p=25% prob

Base Target (Scenario probability)

$7 / p=45% prob

Bear Target (Scenario probability)

$4 / p=30% prob

Analysis 2026-04-15 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-06-30
Second-quarter 2026 preclinical updates on SLN365 and SLN098
Management guided to additional preclinical data for SLN365 and SLN098 in 2Q 2026; these updates matter less than SANRECO but can help test whether the platform still has depth beyond the lead hematology asset [#PR-2026-03-05].
Prob 70.00% • Move 10.00% • Priced-in 55.00%
EVENT2026-09-30
SANRECO Phase 2 topline data in polycythemia vera
Silence says the fully enrolled SANRECO Phase 2 trial of divesiran is on track for topline results in 3Q 2026, with the primary endpoint tied to maintaining hematocrit below 45% without phlebotomies; this is the clearest valuation inflection for the stock [#PR-2025-10-23][#PR-2026-03-05][#10-K-2026-03-05].
Prob 80.00% • Move 45.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Strategic path for zerlasiran and balance-sheet endurance into 2028
2027-03-31
Silence reported $85.1 million of cash and short-term investments at December 31, 2025 and said funds should support operations into 2028, while describing zerlasiran as Phase 3-ready and potentially suitable for a third-party partner; that extends optionality, but monetization is unproven and partner appetite must offset the loss of forward SLN312 development at AstraZeneca [#PR-2026-03-05][#10-K-2026-03-05].
Prob 35% • Move 30% • Priced-in 25%

Risks

AstraZeneca notified Silence on March 4, 2026 that it will not pursue further SLN312 development beyond Phase 1, reducing one external validation path.
Collaboration revenue dropped materially in 2025, increasing dependence on internal execution and future partnering.
Even with runway guided into 2028, prolonged delays or new trial costs could bring dilution risk back sooner than expected.
Leadership transition remains a governance overhang after the December 2025 CEO departure and ongoing search.
SANRECO Phase 2 is the dominant value driver, so a weak or delayed 3Q 2026 readout could reset the equity sharply.

Peers

Symbol	Summary
LRMR	Clinical-stage small-cap biotech with a concentrated lead-asset thesis and sharp repricing around binary development milestones; useful as a risk-profile peer more than a mechanistic peer.
TARA	Another small-cap clinical biotech where valuation is heavily driven by a limited set of program catalysts and financing durability, making it a reasonable event-volatility comp.
FHTX	Less direct scientifically, but still a small-cap development-stage biotech with platform optionality and sentiment that swings with milestone cadence rather than current commercial revenue.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-15

Loading AI feed…

Symbol

Summary

LRMR

Clinical-stage small-cap biotech with a concentrated lead-asset thesis and sharp repricing around binary development milestones; useful as a risk-profile peer more than a mechanistic peer.

TARA

Another small-cap clinical biotech where valuation is heavily driven by a limited set of program catalysts and financing durability, making it a reasonable event-volatility comp.

FHTX

Less direct scientifically, but still a small-cap development-stage biotech with platform optionality and sentiment that swings with milestone cadence rather than current commercial revenue.